Michael Dybbs - Dimension Therapeutics Independent Director
Director
Dr. Michael Dybbs, Ph.D. is an Independent Director of the Company. Dybbs has served as a member of our board of directors since April 2015. Dr. Dybbs is currently a Managing Member of Samsara BioCapital GP, LLC. Prior to that Dr. Dybbs was a partner at New Leaf Venture Partners, L.L.C., where he worked from 2009 to 2016. Prior to joining New Leaf Venture Partners, L.L.C., Dr. Dybbs was a principal at the Boston Consulting Group where he worked from 2005 to 2009. Dr. Dybbs has served as a director of Versartis, Inc. and numerous private life sciences companies since 2015.
| Age | 41 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Phone | 617 401-0011 |
| Web | www.dimensiontx.com |
Dimension Therapeutics Management Efficiency
Dimension Therapeutics' management efficiency ratios could be used to measure how well Dimension Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 5.78 M in liabilities with Debt to Equity (D/E) ratio of 16.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Dimension Therapeutics has a current ratio of 3.26, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Dimension Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Dimension Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Dimension Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Dimension to invest in growth at high rates of return. When we think about Dimension Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jeffrey Graves | FARO Technologies | 56 | |
| John Caldwell | FARO Technologies | 68 | |
| Qin Liu | Xunlei Ltd Adr | 44 | |
| Hongjiang Zhang | Xunlei Ltd Adr | 54 | |
| John Donofrio | FARO Technologies | 56 | |
| Wayne Wisehart | Marchex | 68 | |
| Anne DevereuxMills | Marchex | 53 | |
| Rachel Bennun | Radcom | 71 | |
| Marvin Sambur | FARO Technologies | 70 | |
| Matty Karp | Radcom | 68 | |
| Chuan Wang | Xunlei Ltd Adr | 48 | |
| Yongfu Yu | Xunlei Ltd Adr | 39 | |
| Yuanyuan Chen | Xunlei Ltd Adr | N/A | |
| Jenny Wu | Xunlei Ltd Adr | 38 | |
| Quan Zhou | Xunlei Ltd Adr | 57 | |
| Ian Morris | Marchex | 45 | |
| Uri Har | Radcom | 80 | |
| Dennis Cline | Marchex | 54 | |
| Tao Zou | Xunlei Ltd Adr | 41 | |
| Russell Horowitz | Marchex | 57 | |
| Stephen Cole | FARO Technologies | 66 | |
Management Performance
| Return On Equity | -1.0E-4 | |||
| Return On Asset | -0.0042 |
Dimension Therapeutics Leadership Team
Elected by the shareholders, the Dimension Therapeutics' board of directors comprises two types of representatives: Dimension Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dimension. The board's role is to monitor Dimension Therapeutics' management team and ensure that shareholders' interests are well served. Dimension Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dimension Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mary Thistle, Chief Business Officer | ||
| Michael Dybbs, Independent Director | ||
| Stephanie Haller, Vice President - Clinical Operations | ||
| George Migausky, Independent Director | ||
| Reed Clark, Sr. VP of Pharmaceutical Devel. | ||
| Ben Auspitz, Chairman of the Board, Co-Founder | ||
| Georges Gemayel, Independent Director | ||
| Alan Colowick, Independent Director | ||
| Rishi Gupta, Independent Chairperson of the Board | ||
| Sam Wadsworth, Chief Scientific Officer | ||
| Jean Franchi, CFO and Treasurer | ||
| Samuel Wadsworth, Chief Scientific Officer | ||
| MRCP MBBS, CEO and President and Director | ||
| Arlene Morris, Independent Director | ||
| Eric MD, Chief Medical Officer | ||
| Annalisa Jenkins, CEO, Director | ||
| John Hohneker, Director | ||
| Eric Crombez, Chief Medical Officer |
Dimension Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dimension Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.0E-4 | |||
| Return On Asset | -0.0042 | |||
| Profit Margin | (4.09) % | |||
| Operating Margin | (355.95) % | |||
| Current Valuation | 108.6 M | |||
| Shares Outstanding | 25.21 M | |||
| Shares Owned By Institutions | 71.22 % | |||
| Number Of Shares Shorted | 167.31 K | |||
| Price To Earning | (2.81) X | |||
| Price To Book | 4.13 X |
Pair Trading with Dimension Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dimension Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dimension Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Boeing could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Boeing when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Boeing - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling The Boeing to buy it.
The correlation of Boeing is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Boeing moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Boeing moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Boeing can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Dimension Stock
If you are still planning to invest in Dimension Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dimension Therapeutics' history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |